What the FDA BPC-157 vote means for your bench

An FDA advisory panel voted 8-6 to recommend that BPC-157, a synthetic peptide, stay eligible for compounding pharmacies to prepare. Compounding pharmacies are specialized pharmacies that mix or tailor medicines for individual patients, rather than mass-producing them. The vote is non-binding, meaning the FDA is not required to follow it, and the agency will weigh the panel's input before making a final call.

What BPC-157 actually is

BPC-157 stands for "Body Protection Compound-157," a 15-amino-acid fragment (a short chain built from 15 protein building blocks) originally isolated from gastric juice. Researchers often call it a pentadecapeptide because "penta" means five and "deca" means ten, so 15 in total. Its full sequence is GEPPPGKPADDAGLV, and in solution it folds into a short, loose helix (a spiral shape proteins can take, like a loosely coiled phone cord).

The peptide is of research interest because, in animal and cell studies, it interacts with the nitric oxide (NO) system. NO is a tiny signaling molecule your blood vessels use to relax and widen. BPC-157 also appears to influence the VEGFR2 receptor, the docking site on cells that growth factors bind to in order to build new blood vessels, and it interacts with FAK and Src kinases, two enzymes that help cells stick, crawl, and survive. These are the same pathways involved in wound healing and tissue repair, which is why the compound gets so much attention.

The catch: nearly all of the published work is in rodents, cell cultures, or other preclinical models (experiments done before any human trials). Human safety and dosing data are thin, and the FDA has not approved BPC-157 as a drug.

What the panel actually voted on

The advisory committee was asked whether BPC-157 should remain on the FDA's list of substances that compounding pharmacies can use. The 8-6 vote in favor came despite objections from agency scientists, who reportedly raised concerns about the limited human data and the lack of an FDA-approved drug product to base compounding on. A "yes" vote here does not mean the FDA has approved BPC-157. It means a majority of outside experts think compounders should still be able to prepare it under pharmacy rules.

For researchers who handle the raw lyophilized powder (freeze-dried peptide that looks like a fluffy white cake) at the bench, the regulatory status matters less than the practical one: the supply chain is still mostly research-grade.

Why this matters at your bench

Most BPC-157 in the research market is sold as a lyophilized powder in sealed vials, with purity verified by HPLC (high-performance liquid chromatography, a lab technique that separates and measures the components of a mixture) and identity confirmed by mass spectrometry (a method that weighs molecules to confirm they are exactly what the label says). That is the standard to look for, regardless of any FDA vote.

Once you reconstitute it (add sterile water to the powder so it dissolves into a liquid you can work with), the clock starts. Dissolved peptides are far less stable than the dry powder. They can degrade through hydrolysis (water molecules slowly chopping the peptide chain apart), oxidation (oxygen stealing electrons and breaking sensitive bonds), and aggregation (peptides clumping together into useless blobs). Bacteriostatic water (sterile water with a small amount of benzyl alcohol to slow bacterial growth) is the standard diluent for multi-use vials because it keeps the solution cleaner for repeated draws, but it does not stop chemical degradation.

Three habits protect your vials. First, always check the certificate of analysis (CoA), the paper (or PDF) that lists the actual purity and test results for your specific lot, before you reconstitute. Second, reconstitute gently: let the diluent run down the inside of the vial wall instead of squirting it straight onto the powder, which can shear (mechanically tear apart) the peptide. Third, split your stock into single-use aliquots (small, pre-measured portions) so you only thaw what you need.

The bottom line for researchers

The FDA vote is a regulatory signal, not a quality endorsement. Your results still depend on what is in the vial: a verified CoA, clean diluent, sterile technique, and cold storage. Treat the powder like the fragile reagent it is, and your data will thank you.

Frequently asked questions

Did the FDA approve BPC-157?

No. An advisory panel voted 8-6 to keep it eligible for compounding, but the vote is non-binding and the FDA has not approved BPC-157 as a drug.

What is BPC-157 made of?

It is a 15-amino-acid fragment called a pentadecapeptide, with the sequence GEPPPGKPADDAGLV, originally isolated from gastric juice.

How should reconstituted BPC-157 be stored?

Refrigerate at 2-8°C and use within 2-4 weeks, or freeze in single-use aliquots at -20°C for longer storage. Avoid room temperature.

Prompted by this coverage at Google News →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about BPC-157

• The "stable" in the name does not mean stable in your vial. BPC-157 is called a stable gastric pentadecapeptide because it held up in gastric juice in the original studies, not because it lasts once you add water. In solution it can still break down through hydrolysis, oxidation, and clumping, so a reconstituted vial has a much shorter working life than the dry powder.
• Almost all the published data is preclinical. The receptor and pathway findings people quote (nitric oxide, VEGFR2, FAK, Src) come mostly from rodents and cell cultures. They describe what has been studied in models, not settled facts about people. Treat them as background for bench work, not conclusions.
• The FDA panel vote is not a purity stamp. An advisory vote on compounding eligibility says nothing about what is inside a given research vial. Two lots can both be legal to compound and still differ in purity, so the certificate of analysis (CoA) for your specific lot is what tells you what you actually have.
• "No reported toxicity" in a review is not a handling guideline. Statements like that come from animal studies and refer to the research setting, not to safe casual handling at a bench. It is a research reagent, so keep normal lab practices: sealed storage, clean diluent, and sterile technique.
• Identity gets assumed instead of confirmed. Vials labeled BPC-157 can be the free peptide or a salt form, and the sequence (GEPPPGKPADDAGLV) can be mislabeled. Confirm identity by mass spectrometry and purity by HPLC rather than trusting the label alone.

From our bench: If you have reconstituted a BPC-157 lot, we want your real numbers. Tell us the HPLC purity printed on your CoA, the diluent you used, your storage temperature, and how many days passed before you first saw cloudiness or a precipitate in the vial. We will fold verified reader observations into this page. Please share only measurements you actually recorded, with no estimated or filled-in values.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. PubChem, BPC-157 (CID 9941957), C62H98N16O22
5. Seiwerth et al., Stable Gastric Pentadecapeptide BPC 157 and Wound Healing, Front Pharmacol 2021 (PMID 34267654)
6. Multifunctionality and Possible Medical Application of the BPC 157 Peptide: Literature and Patent Review, Pharmaceuticals (Basel) 2025 (PMID 40005999)